mBio · 2022 · 26 citations · 39 references
Life SciencesInfectious DiseasesPharmacologyAntimicrobial PharmacologyAntimicrobial PharmacotherapyAntimicrobial ResistanceAntibacterial PharmacologyAntibacterial ResistanceAntibiotic ResistanceAntibiotic Resistance MechanismsBeta-lactam ResistanceMultidrug ResistanceAcinetobacter Baumannii InfectionAcinetobacter Baumannii ResistanceCellular Zinc OverloadMultidrug-resistant OrganismsMultidrug-resistant PathogensTetracycline AntibioticsTreatment Of Bacterial ResistanceVentilator-associated Pneumonia Treatment
Within intensive care unit settings, multidrug-resistant (MDR) Acinetobacter baumannii is a major cause of ventilator-associated pneumonia, and hospital-associated outbreaks are becoming increasingly widespread. Antibiotic treatment of A. baumannii infection is often compromised by MDR strains resistant to last-resort β-lactam (e.g., carbapenems), polymyxin, and tetracycline class antibiotics. During the on-going COVID-19 pandemic, secondary bacterial infection by A. baumannii has been associated with a 2-fold increase in COVID-19-related mortality. With a rise in antibiotic resistance and a reduction in new antibiotic discovery, it is imperative to investigate alternative therapeutic regimens that complement the use of current antibiotic treatment strategies. Rescuing the efficacy of existing therapies for the treatment of MDR A. baumannii infection represents a financially viable pathway, reducing time, cost, and risk associated with drug innovation.
39
Lars Lannfelt, Kaj Blennow, Henrik Zetterberg et al. · The Lancet Neurology · 2008 · 712 citations
Medicine, Neuroscience, Pharmacology +17
Emergence of plasmid-mediated high-level tigecycline resistance genes in animals and humans
Tao He, Ran Wang, Dejun Liu et al. · Nature Microbiology · 2019 · 711 citations
A Molecular Mechanism for Bacterial Susceptibility to Zinc
Christopher A. McDevitt, Abiodun D. Ogunniyi, Eugene Valkov et al. · PLoS Pathogens · 2011 · 495 citations · Full text